120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
C反应蛋白-淋巴细胞-白蛋白（CALLY）指数与心血管-肾脏-代谢综合征3期患者心血管疾病的关联及预测价值
Authors Yuan M, Li L, Hou Y, Wei L, Zhang R , Jiang H
Received 11 November 2025
Accepted for publication 23 January 2026
Published 29 January 2026 Volume 2026:19 576278
DOI https://doi.org/10.2147/IJGM.S576278
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Redoy Ranjan
Mei Yuan,1,* Luohua Li,2,* Yueyuan Hou,1,* Ling Wei,1 Rou Zhang,3 Hongying Jiang1
1Department of Nephrology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650101, People’s Republic of China; 2Department of Nephrology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830054, People’s Republic of China; 3Department of Sleep Medicine, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650101, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hongying Jiang, Department of Nephrology, The Second Hospital Affiliated to Kunming Medical University, No. 374, Dianmian Avenue, Kunming, Yunnan Province, 650101, People’s Republic of China, Tel +86 13033371998, Email 1627248965@qq.com
Background: Cardiovascular–kidney–metabolic (CKM) syndrome stage 3 is a high-risk condition for cardiovascular disease (CVD), characterized by intertwined metabolic dysregulation, chronic inflammation, and immune dysfunction. This study aimed to evaluate the association and predictive value of the C-reactive protein–lymphocyte–albumin (CALLY) index for CVD in this population.
Methods: In a retrospective cohort of patients with CKM stage 3, the CALLY index was calculated from baseline laboratory data. Its association with incident CVD was assessed using multivariable Cox proportional hazards models. To test robustness, sensitivity and subgroup analyses were performed. Predictive performance was evaluated by time-dependent receiver operating characteristic (ROC) analysis, integrated discrimination improvement (IDI), and net reclassification improvement (NRI).
Results: Among 826 patients followed for a median of 51 months, a higher CALLY index was independently associated with a lower risk of CVD (adjusted hazard ratio 0.37, 95% CI: 0.25– 0.55). The association remained robust in sensitivity and subgroup analyses. The index demonstrated superior discrimination for CVD (area under the curve 0.806, 95% CI: 0.774– 0.838). The CALLY index provided significant incremental predictive value compared to using its individual components (CRP, albumin, or lymphocyte count alone).
Conclusion: A lower CALLY index is independently associated with an increased risk of CVD in patients with CKM stage 3 and exhibits robust predictive performance. This readily available composite biomarker may aid in cardiovascular risk stratification for this high-risk group.
Keywords: cardiovascular disease, metabolic dysfunction, inflammation, biomarker
1Department of Nephrology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650101, People’s Republic of China; 2Department of Nephrology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, 830054, People’s Republic of China; 3Department of Sleep Medicine, The First People’s Hospital of Yunnan Province, Kunming, Yunnan, 650101, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hongying Jiang, Department of Nephrology, The Second Hospital Affiliated to Kunming Medical University, No. 374, Dianmian Avenue, Kunming, Yunnan Province, 650101, People’s Republic of China, Tel +86 13033371998, Email 1627248965@qq.com
Background: Cardiovascular–kidney–metabolic (CKM) syndrome stage 3 is a high-risk condition for cardiovascular disease (CVD), characterized by intertwined metabolic dysregulation, chronic inflammation, and immune dysfunction. This study aimed to evaluate the association and predictive value of the C-reactive protein–lymphocyte–albumin (CALLY) index for CVD in this population.
Methods: In a retrospective cohort of patients with CKM stage 3, the CALLY index was calculated from baseline laboratory data. Its association with incident CVD was assessed using multivariable Cox proportional hazards models. To test robustness, sensitivity and subgroup analyses were performed. Predictive performance was evaluated by time-dependent receiver operating characteristic (ROC) analysis, integrated discrimination improvement (IDI), and net reclassification improvement (NRI).
Results: Among 826 patients followed for a median of 51 months, a higher CALLY index was independently associated with a lower risk of CVD (adjusted hazard ratio 0.37, 95% CI: 0.25– 0.55). The association remained robust in sensitivity and subgroup analyses. The index demonstrated superior discrimination for CVD (area under the curve 0.806, 95% CI: 0.774– 0.838). The CALLY index provided significant incremental predictive value compared to using its individual components (CRP, albumin, or lymphocyte count alone).
Conclusion: A lower CALLY index is independently associated with an increased risk of CVD in patients with CKM stage 3 and exhibits robust predictive performance. This readily available composite biomarker may aid in cardiovascular risk stratification for this high-risk group.
Keywords: cardiovascular disease, metabolic dysfunction, inflammation, biomarker